| | Webinar: How Providence is Tapping into the Benefits of Patient Activation Tuesday, November 10 | 1pm ET / 10am PT Our healthcare industry has only begun to tap the benefits of patient activation to avoid disruption & improve clinical outcomes, operational efficiency & financial performance. In this session, a panel of experts will review Providence’s My COVID Diary & My Surgical Journey projects & their ability to deliver patient-centric care, & measurable quality, revenue & patient satisfaction improvements. Register Now! |
AstraZeneca CEO blames trial delays, not manufacturing, for COVID vaccine delivery shortfall Cigna says health utilization continued to rebound in Q3 Hologic’s diagnostic sales rocket 375% as COVID-19 demand continues to rise Biopharma roundup: Gilead's Veklury absent from WHO's drug procurement plan Healthcare roundup: Fitbit partners with DOD to develop wearable that detects COVID-19 Parexel pens blood, serology pact with Drawbridge Health and Synexa for COVID-19 trials Many pediatricians say vaccines, visits dropped off amid COVID-19. Nemours says it bucked the trend Charles River Labs sees strong Q3 growth, CEO lauds 'resilience of our business model' Featured Story | By Angus Liu AstraZeneca had an order to supply 100 million doses of the University of Oxford’s COVID-19 vaccine to the U.K., including 30 million doses by September. The drugmaker missed that deadline, but according its CEO, it was due to manufacturing consideration after a clinical trial delay. read more |
| |
|---|
|
Top Stories By Paige Minemyer,Robert King Cigna posted $1.4 billion in profit for the third quarter, performance it says is bolstered by its newly rebranded Evernorth subsidiary. read more By Conor Hale After seeing its overall sales slip last quarter, Hologic’s COVID-19 testing sales have continued to skyrocket—powering the company’s most recent quarterly income to over $1.3 billion. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner AstraZeneca chief Pascal Soriot deflected reports of vaccine delivery delays. Bangladesh secured 30 million AZ doses as Chile OK'd a clinical trial of the shot. WHO won't include Gilead's Veklury in its plan to supply drugs to low-income countries. And the U.S. recorded more than 100,000 new cases Wednesday. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Ben Adams Major CRO Parexel has signed up with bioanalytics company Synexa Life Sciences and blood drawing specialist Drawbridge Health for a “more streamlined solution for blood sample collection and serology testing.” read more By Tina Reed While plenty of adult primary care as well as pediatric practices continue to report sluggish returns in visits among their patients, Nemours officials say they have been able to return to somewhat normal visit volumes and actually increased immunizations among kids year-to-date. Here's how. read more By Ben Adams As an early-stage CRO, Charles River Labs has escaped the broader damage of its peers and is still steaming ahead in the third quarter with a jump in revenue. read more |
